Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03453619 · ClinicalTrials.gov registry record · Phase 2
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
A Phase 2 study of Lupus Nephritis and IgA Nephropathy, sponsored by Apellis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 17
- Study locations
NCT03453619 is a Phase 2 study of Lupus Nephritis and IgA Nephropathy that has completed, run by Apellis Pharmaceuticals. The registered enrollment target is 21 participants, below the 310-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (93% lower). The trial reports 17 study locations across 14 states.
The verdict
NCT03453619, a Phase 2 study of Lupus Nephritis and IgA Nephropathy, has completed, sponsored by Apellis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
Conditions Studied
Interventions
- DRUG APL-2
Study Locations (17)
Colorado
- Children's Hospital Colorado - Aurora
- HealthONE Physician Care, Rocky Mountain Hospital for Children - Denver
New York
- Davita Clinical Research - The Bronx
- Westchester Medical Center - Valhalla
Virginia
- Washington Nephrology Associates - Alexandria
- Davita Clinical Research - Chesapeake
California
- Stanford University - Stanford
District of Columbia
- Washington Nephrology Associates - Washington D.C.
Florida
- Horizon Research Group - Coral Gables
Georgia
- Emory University - Atlanta
Indiana
- American Research LLC - Jeffersonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-02-26 |
| Est. Completion | 2023-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03453619
The ClinicalTrials.gov registry entry for NCT03453619 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 310-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (93% lower). The listed sponsor is Apellis Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Lupus Nephritis appearing as the primary indexed condition, and to 1 intervention - of which APL-2 is the first listed.
NCT03453619 reports 17 study locations spanning 14 distinct geographic areas - top geographies include Colorado, New York, Virginia.
Frequently Asked Questions
What is clinical trial NCT03453619 about?
NCT03453619 is a clinical study titled "Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies". This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
What is the current status of trial NCT03453619?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2018-02-26. Estimated completion is 2023-08-26.
What conditions does trial NCT03453619 study?
This clinical trial studies the following conditions: Lupus Nephritis, IgA Nephropathy, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease.
What interventions are being tested in trial NCT03453619?
The interventions under investigation include: APL-2 (DRUG).
Who is sponsoring clinical trial NCT03453619?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03453619 being conducted?
This trial has 17 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
RECRUITING · Phase 2
-
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
RECRUITING · Phase 2
-
VIBRANT: VIB4920 for Active Lupus Nephritis
RECRUITING · Phase 2
-
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
RECRUITING · Phase 2
-
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.